Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Although great effort is being expended in the development of cancer immunotherapies, it is surprising that global lymphopenia and its various dimensions are not being systematically assessed in cancer patients. The incident pathologies associated with various immunosuppressed conditions such as those found in HIV infection have taught us that measuring various T cell populations including CD4 provides the clinician with a reliable measure for gauging the risk of cancer and opportunistic infections. Importantly, recent data emphasize the key link between lymphocyte T cell counts and overall survival in cancer patients receiving chemotherapy. Treatment of immunocompromised patients with interleukin-7 (IL-7), a critical growth and homeostatic factor for T cells, has been shown to produce a compelling profile of T cell reconstitution. The clinical results of this investigational therapy confirm data obtained from numerous preclinical studies and demonstrate the long-term stability of this immune reconstitution, not only on CD4 but also on CD8 T cells, involving recent thymic emigrants as well as naive, memory, and central memory T cells. Furthermore, IL-7 therapy also contributes to restoration of a broadened diversity of the T cell repertoire as well as to migration of these cells to lymph nodes and tissues. All these properties support the initiation of new clinical studies aimed at reconstituting the immune system of cancer patients before or immediately after chemotherapy in order to demonstrate a potentially profound increase in overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×
“established the association between increased survival and a high level of infiltrating memory T cells (CD45RO+), an absence of signs of early metastatic invasion, and a less advanced pathological state [35].”
BackgroundGuadalupe, M., Reay, E., Sankaran, S., Prindiville, T., Flamm, J., McNeil, A., & Dandekar, S. (2003) · Journal of Virology · doi:10.1128/jvi.77.21.11708-11717.2003 · Cited by 866 · cited 1×
“In HIV infection, it took almost 20 years for the medical community to understand the significance of severe lymphopenia in the gut and its key role in the persistence of T cell activation [16, 17].”
BackgroundDefective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency
Puel, A., Ziegler, S. F., Buckley, R. H., & Leonard., W. J. (1998) · Nature Genetics · doi:10.1038/3877 · Cited by 813
Mackall, C. L., Fleisher, T. A., Brown, M. R., Andrich, M. P., Chen, C. C., Feuerstein, I. M., Magrath, I. T., Wexler, L. H., Dimitrov, D. S., & Gress, R. E. (1997) · Blood · doi:10.1182/blood.v89.10.3700 · Cited by 400
Roifman, C. M., Zhang, J., Chitayat, D., & Sharfe, N. (2000) · Blood · doi:10.1182/blood.v96.8.2803 · Cited by 177
Porrata, L. F., Ristow, K., Habermann, T., Inwards, D. J., Micallef, I. N., & Markovic, S. N. (2010) · American Journal of Hematology · doi:10.1002/ajh.21849 · Cited by 124 · cited 1×
“studied the relapse rate of 149 Mayo clinic patients with diffuse large B cell lymphoma treated with rituxan, cyclophosphamide, adrimamycine, vincristine, and prednisone [22].”
Background
Cited by
Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70001-x · Cited by 1,442
How the ageing microenvironment influences tumour progression
Fane, M., & Weeraratna, A. T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0222-9 · Cited by 849
Ménétrier-Caux, C., Ray-Coquard, I., Blay, J.-Y., & Caux, C. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0549-5 · Cited by 339
The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer?
Boomer, J. S., Green, J. M., & Hotchkiss, R. S. (2014) · Virulence · doi:10.4161/viru.26516 · Cited by 317
Chemoimmunotherapy: Reengineering Tumor Immunity
Chen, G., & Emens, L. A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1388-0 · Cited by 242
Metadata
- Authors
- Morre, M., & Beq, S.
- Venue
- Targeted Oncology
- Published
- 2012-03
- Volume
- 7
- Issue
- 1
- Pages
- 55-68
- ISSN
- 1776-2596 (ISSN-L)
- 1776-260X
- OpenAlex
- W1974971484
- Cited by
- 51
- References
- 6
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. https://app.cochat.ai/papers/10.1007/s11523-012-0210-4
- The paper
- Morre, M., & Beq, S. (2012). Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Targeted Oncology. https://doi.org/10.1007/s11523-012-0210-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.